Clinical trial · Observational
Gene Expression, Immunological Status and Metabolome in Glioma Patients
Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study on glioma patients treated with brain surgery is focusing on the analysis of their transcriptome expression profile measured in two immune cell populations, CD4+ T cells and CD56+ NK cells. The results of analysis will be compared to the reference data of healthy population. Furthermore, the metabolomic and immunological status will also be monitored and compared to healthy group reference data, before and after the surgery\*. With comparative crossomics analysis the investigators intend to possibly identify new diagnostic and prognostic biological markers for the relapse of the disease. The results are expected to convey a deeper insight into pathophysiology of the glioma as well as into the mechanisms of the current surgical therapy. \* The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB (Gruden et al. 2012).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Other | — | UNRESOLVED |
| Glioma resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Glioma patients
- interventionNames
- Procedure: Glioma resection
- Other: Blood sampling
Primary outcomes (3)
- measure
- Transcriptome profile of CD4+ T and CD56+ NK cells
- timeFrame
- within 10 days before surgery
- measure
- Transcriptome profile of CD4+ T and CD56+ NK cells
- timeFrame
- one day after surgery
- measure
- Transcriptome profile of CD4+ T and CD56+ NK cells
- timeFrame
- within 10 days after surgery
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * malignant glioma = glioblastoma (WHO IV) patients Exclusion Criteria: * pregnancy * metastases
References
Publications (1)
- BACKGROUNDGruden K, Hren M, Herman A, Blejec A, Albrecht T, Selbig J, Bauer C, Schuchardt J, Or-Guil M, Zupancic K, Svajger U, Stabuc B, Ihan A, Kopitar AN, Ravnikar M, Knezevic M, Rozman P, Jeras M. A "crossomics" study analysing variability of different components in peripheral blood of healthy caucasoid individuals. PLoS One. 2012;7(1):e28761. doi: 10.1371/journal.pone.0028761. Epub 2012 Jan 12. PMID 22253695